Novartis scores FDA clearance for combo blood pressure drug
The FDA has approved Novartis' Exforge HCT, a blood pressure treatment that combines three medications in a single pill.

Exforge HCT combines the number one prescribed calcium channel blocker, angiotensin receptor blocker and diuretic in one pill for patients who have tried taking dual combinations of these classes of blood pressure medications without success, according to the Basel, Switzerland-based company. The approval was based on a clinical trial of Exforge HCT of more than 2,000 patients.

Novartis said that Exforge and Exforge HCT will be offered at the same price in the U.S. on a dose-equivalent basis, essentially providing the added diuretic in Exforge HCT at no additional cost.